New hope for kids with severe psoriasis: biosimilar drug shows promise
NCT ID NCT05803187
First seen Mar 14, 2026 · Last updated May 01, 2026 · Updated 6 times
Summary
This study looked at how well and how safely a biosimilar drug called QLETLI (adalimumab) works for children and teenagers aged 4 to 17 with severe plaque psoriasis. 80 participants were treated and monitored for 24 weeks. The main goal was to see if the drug could significantly clear or improve their skin symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, 200072, China
Conditions
Explore the condition pages connected to this study.